Somatostatin Analogs Market Research Report, By Types (Octreotide, Lanreotide, and Pasireotide), By Applications (Neuroendocrine Tumor (NET), Acromegaly and others), By Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

Somatostatin Analogs Market Synopsis

Somatostatin Analogs Market is expected to hold a value of about USD 8,640 Million by 2025, and it is projected to grow at a CAGR of 6.8% from 2019 to 2025.

Somatostatin analogs are the drugs that stop the excessive hormone secretion in the body. Neuroendocrine Tumors (NETs) and Acromegaly, a rare hormonal disorder, are the most common indications treated with somatostatin analogs. Some of the other common tumors treated with Somatostatin Analogs are carcinoid tumors, glucagonomas, VIPomas, and GH-secreting tumors. Besides this, Somatostatin Analogs are also used to treat Cushing's syndrome.

Somatostatin analogs have been commercially available for more than three decades. Earlier, the market for somatostatin analogs was dominated by a couple of players including Novartis, and Ipsen. However, the scenario has changed in last few years as the demand for these drugs is increasing. As a result, the number of players is getting involved in the development of generic somatostatin analogs as well as the novel drugs.

Somatostatin Analogs Market Influencer

The increasing R&D activity in the somatostatin analogs for the development of novel drugs is the major factor instrumental in the growth of the somatostatin analogs Market.

Market Drivers

• Increasing research and development activity in the somatostatin analogs market has resulted in the increased usage of already existing drug molecules. Also, for these R&D activities, companies are generating research funding and investments in the market, which positively impacts the market growth. As in November 2019, there are 79, 25, and 11 clinical studies (Active/Recruiting) that are being conducted on Octreotide, Lanreotide, and Pasireotide, respectively. Moreover, there are about 38 clinical studies being conducted on Acromegaly, out of which 27 studies involve the use of Somatostatin Analogs. Similarly, 1,075 clinical studies are being conducted on Neuroendocrine tumors, out of which 85 studies involve the use of somatostatin analogs.

• Increasing the number of players involved in the development of Somatostatin Analogs.

• Rising incidences of NETs. It is estimated that, in the US, more than 12,000 patients are diagnosed with Neuroendocrine Tumors (NETs) each year; and nearly 170,000 people are living with the disease as of 2019. Rise in the disease cases creates the demand for the treatment options resulting in the growth of the market

• Increasing efforts to increase awareness about Acromegaly. In November 2017, the World Alliance of Pituitary Organizations (WAPO) launched a global awareness campaign, in which November 1st is celebrated as the Acromegaly Awareness Day every year. The main purpose of this campaign is to raise awareness about the rare disease and reduce the time it takes to get a diagnosis for people with Acromegaly.

Market Restraints

• Lack of awareness leading to a high number of undiagnosed people


• Availability of the alternative treatment options for the treatment of NETs and Acromegaly.

Somatostatin Analogs Market Segmentation

By Type

• Octreotide: It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. It is the first-ever type of Somatostatin Analogue. It is also the most commonly used somatostatin analog, as it has been commercially available for a long time and has also provided positive results over the years. The top brands of Octreotide are ‘Sandostatin,’ and ‘Sandostatin Lar’ manufactured by Novartis. Some of the generic versions are Otide, Okerson, Octride, and Octronis among others. Octreotide is expected to hold the largest share in the global market during the assessment period.

• Lanreotide: It is a long-acting analog manufactured by Ipsen Pharmaceuticals. Lanreotide is marketed as Somatuline. It was approved by FDA in 2017. Lanreotide is commonly used for the treatment of acromegaly and carcinoid tumors.

• Pasireotide: It is a long-acting cyclic hexapeptide manufactured initially by Novartis. It is marketed under the brand name Signifor. Pasireotide is expected to be the fastest-growing segment owing to the factors including increasing uptake of the drugs for the treatment of Cushing’s syndrome and other associated medical conditions.

By Treatment

• Neuroendocrine Tumor (NET): Neuroendocrine tumors are the largest segment in the global somatostatin analogs market. The major types of neuroendocrine tumors treated with the somatostatin analogs are carcinoid tumors, glucagonomas, VIpomas, and Growth Hormone Secreting Tumors, among others. Somatostatin analogs are used to block the hormone release in these endocrine tumors.

• Acromegaly: Acromegaly is caused by the hypersecretion of Growth hormone. Apart from surgery, Somatostatin analogs are used as the primary therapy for the treatment. The treatment goals for acromegaly are to reduce the tumor size and to maintain GH and IGF-1 within normal ranges. Somatostatin analogs inhibit the release of GH from the pituitary gland and help in reducing the growth of the tumors.

• Cushing’s Syndrome: Cushing’s syndrome, sometimes also called hypercortisolism is caused when the body excessively produces the hormone cortisol. Moreover, it can occur due to exposure to high levels of the hormone cortisol for a long time and also by the use of oral corticosteroid medication.

• Others: The other segment includes chemotherapy, malignant bowel obstruction, and HIV-related diarrhea.

By Region

• Americas: Countries such as the US and Canada have been at the forefront of the healthcare industry over the years. High awareness about NETs, high per capita disposable income, and the emergence of new companies such as Crinetics Pharmaceuticals and Chiasma, Inc., among others for development of the generic versions of the somatostatin analogs are some of the contributing factors for the growth of the somatostatin analogs market in this region.

• Europe: Europe is the second-largest market for somatostatin analogs. High revenues generated by the major market players such as Novartis AG and Ipsen Pharma, among others are influencing the growth of the regional market and increasing prevalence of Acromegaly and NETs is also creating the demand for the treatment options resulting in the growth in the region. For instance, each year, about 300 new patients are diagnosed with Acromegaly in Germany.

• Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global somatostatin analogs market. This region has been witnessing an increase in the number of people afflicted with acromegaly and NETs. In 2018, about 22,402 new cases of pancreatic cancer were registered in South East Asia. The increasing prevalence of these diseases is an important factor in the growth of the somatostatin analogs market in Asia-Pacific region.

• Middle East & Africa: It is the smallest market due to limited healthcare infrastructure, lack of awareness about the disease condition, and low per capita disposable incomes in underdeveloped regions of Africa.

Key Players

• Novartis AG (Switzerland)


• Ipsen Pharma (France)


• Fresenius Kabi (Germany)


• Peptron (South Korea)


• Pfizer Inc. (US)


• Teva Pharmaceuticals Inc. (Israel)

Potential Entrant in the Somatostatin Analogs Market

• Camurus AB (Sweden)


• Chiasma, Inc. (US)


• CRINETICS PHARMACEUTICALS (US)


• Dauntless Pharmaceuticals (US)


• Midatech Pharma plc (UK)


• Sun Pharmaceutical Industries Ltd (India)